Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2025 EPS estimates for Neumora Therapeutics in a research report issued on Tuesday, May 13th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.44) per share for the quarter, down from their prior estimate of ($0.42). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics' Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($0.23) EPS.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.02).
A number of other brokerages have also recently issued reports on NMRA. Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. Stifel Nicolaus cut shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and reduced their price target for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. Bank of America restated an "underperform" rating and issued a $1.00 price objective (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. William Blair downgraded Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Monday, March 10th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $9.29.
Check Out Our Latest Stock Analysis on Neumora Therapeutics
Neumora Therapeutics Stock Performance
Shares of Neumora Therapeutics stock opened at $0.62 on Thursday. The firm has a fifty day moving average of $0.88 and a two-hundred day moving average of $4.50. The stock has a market capitalization of $99.49 million, a price-to-earnings ratio of -0.33 and a beta of 2.96. Neumora Therapeutics has a 52 week low of $0.61 and a 52 week high of $17.19.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $61,000. PNC Financial Services Group Inc. bought a new position in shares of Neumora Therapeutics in the 4th quarter valued at $64,000. Quantbot Technologies LP acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $92,000. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $117,000. Finally, EntryPoint Capital LLC bought a new stake in Neumora Therapeutics during the 4th quarter worth $135,000. Institutional investors own 47.65% of the company's stock.
Neumora Therapeutics Company Profile
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
